期刊
CELL REPORTS MEDICINE
卷 2, 期 7, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xcrm.2021.100354
关键词
-
资金
- Children's Healthcare of Atlanta
- Georgia Research Alliance
- Donaldson Trust
- National Institute of Allergy and Infectious Diseases and the Office of the Director of the National Institutes of Health [UM1AI068618-14S1, UM1AI069481-14S1, UM1A057266S1, U19AI05726617S1, 1U54CA260563, U19AI090023, ORIP/OD P51OD011132, T32AI074492]
- Oliver S. and Jennie R.Donaldson Charitable Trust
- Paul G. Allen Family Foundation [12931]
- Seattle COVID-19 Cohort Study (Fred Hutchinson Cancer Research Center)
- Joel D. Meyers Endowed Chair
- An Emory EVPHA Synergy Fund award
- COVID-CatalystI3 Funds from the Woodruff Health Sciences Center
- Center for Childhood Infections and Vaccines
- Woodruff Health Sciences Center 2020 COVID-19 CURE Award
- Vital Projects/Proteus funds
The study reveals that COVID-19 patients have durable broad-based immune responses, including the continuous generation of antibodies, memory B cells, and polyfunctional T cells, which help to rapidly generate antibody responses against virus re-exposure or vaccination.
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist longterm in recovered COVID-19 patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据